Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDDate | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/04/2023 | Q2 2023 | -$0.34 | -$0.18 | 0.16 | $0 | |
05/05/2023 | Q1 2023 | $0.39 | -$0.24 | -0.63 | $0 | |
03/14/2023 | Q4 2022 | $0.58 | -$0.84 | -1.42 | $0 | |
11/07/2022 | Q3 2022 | $0.49 | -$0.37 | -0.86 | $0 | |
08/15/2022 | Q2 2022 | $0.39 | -$0.47 | -0.86 | $0 | |
05/10/2022 | Q1 2022 | -$0.38 | $0 | |||
03/29/2022 | Q4 2021 | -$0.22 | -$0.25 | -0.03 | $0 | |
11/12/2021 | Q3 2021 | -$0.20 | $0 | |||
08/16/2021 | Q2 2021 | -$0.14 | $0 | |||
05/17/2021 | Q1 2021 | -$0.08 | $0 |
Pardes Biosciences, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Sunday, November 5th, 2023 based off last year's report dates.
In the previous quarter, Pardes Biosciences, Inc. (:PRDS) reported $0.18 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.34 by $0.52.
The conference call for Pardes Biosciences, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Pardes Biosciences, Inc.'s latest earnings report can be read online.
Pardes Biosciences, Inc. (:PRDS) has a recorded net income of $0. Pardes Biosciences, Inc. has generated $-1.61 earnings per share over the last four quarters.
Pardes Biosciences, Inc. (:PRDS) has a price-to-earnings ratio of -1.36 and price/earnings-to-growth ratio is -0.01.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED